Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
10 recherche sur le mot-clé 'Melatonin'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes / Beth A. MALOW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)
[article]
Titre : Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes Type de document : Texte imprimé et/ou numérique Auteurs : Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur Année de publication : 2012 Article en page(s) : p.1729-1737 Langues : Anglais (eng) Mots-clés : Melatonin Insomnia Actigraphy Clinical trial Children’s sleep habits questionnaire Child behavior checklist Autism diagnostic observation schedule Index. décimale : PER Périodiques Résumé : Supplemental melatonin has shown promise in treating sleep onset insomnia in children with autism spectrum disorders (ASD). Twenty-four children, free of psychotropic medications, completed an open-label dose-escalation study to assess dose–response, tolerability, safety, feasibility of collecting actigraphy data, and ability of outcome measures to detect change during a 14-week intervention. Supplemental melatonin improved sleep latency, as measured by actigraphy, in most children at 1 or 3 mg dosages. It was effective in week 1 of treatment, maintained effects over several months, was well tolerated and safe, and showed improvement in sleep, behavior, and parenting stress. Our findings contribute to the growing literature on supplemental melatonin for insomnia in ASD and inform planning for a large randomized trial in this population. En ligne : http://dx.doi.org/10.1007/s10803-011-1418-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178
in Journal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1729-1737[article] Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes [Texte imprimé et/ou numérique] / Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur . - 2012 . - p.1729-1737.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1729-1737
Mots-clés : Melatonin Insomnia Actigraphy Clinical trial Children’s sleep habits questionnaire Child behavior checklist Autism diagnostic observation schedule Index. décimale : PER Périodiques Résumé : Supplemental melatonin has shown promise in treating sleep onset insomnia in children with autism spectrum disorders (ASD). Twenty-four children, free of psychotropic medications, completed an open-label dose-escalation study to assess dose–response, tolerability, safety, feasibility of collecting actigraphy data, and ability of outcome measures to detect change during a 14-week intervention. Supplemental melatonin improved sleep latency, as measured by actigraphy, in most children at 1 or 3 mg dosages. It was effective in week 1 of treatment, maintained effects over several months, was well tolerated and safe, and showed improvement in sleep, behavior, and parenting stress. Our findings contribute to the growing literature on supplemental melatonin for insomnia in ASD and inform planning for a large randomized trial in this population. En ligne : http://dx.doi.org/10.1007/s10803-011-1418-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study / Laurie K. MCLAY in Research in Autism Spectrum Disorders, 93 (May 2022)
[article]
Titre : Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study Type de document : Texte imprimé et/ou numérique Auteurs : Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur Article en page(s) : 101948 Langues : Anglais (eng) Mots-clés : Autism Attention deficit hyperactivity disorder Melatonin Sleep Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101948[article] Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study [Texte imprimé et/ou numérique] / Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur . - 101948.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101948
Mots-clés : Autism Attention deficit hyperactivity disorder Melatonin Sleep Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475 Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial / Masaharu HAYASHI in Journal of Autism and Developmental Disorders, 52-6 (June 2022)
[article]
Titre : Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial Type de document : Texte imprimé et/ou numérique Auteurs : Masaharu HAYASHI, Auteur ; Kazuo MISHIMA, Auteur ; Michio FUKUMIZU, Auteur ; Hiroyuki TAKAHASHI, Auteur ; Yuko ISHIKAWA, Auteur ; Izumi HAMADA, Auteur ; Hideyuki SUGIOKA, Auteur ; Osamu YOTSUYA, Auteur ; Yushiro YAMASHITA, Auteur Article en page(s) : p.2784-2793 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Melatonin Randomized controlled trial Sleep hygiene interventions Sleep problems Index. décimale : PER Périodiques Résumé : Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD). In a phase 3 randomized, placebo-controlled clinical trial, we administered 1-mg melatonin (n=65), 4-mg melatonin (n=65), or placebo (n=66) to196 children with ASD once daily before bedtime under adequate sleep hygiene interventions. The primary outcome was sleep onset latency (SOL) assessed with the electronic sleep diary. SOL shortened significantly in the 1- and 4-mg melatonin groups compared to the placebo group (- 22.0, - 28.0, and - 5.0 min, respectively; p?0.0001 each). This therapeutic regimen of melatonin is a reasonable clinical approach to cope with ASD-emergent difficulties in children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05139-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=474
in Journal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2784-2793[article] Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial [Texte imprimé et/ou numérique] / Masaharu HAYASHI, Auteur ; Kazuo MISHIMA, Auteur ; Michio FUKUMIZU, Auteur ; Hiroyuki TAKAHASHI, Auteur ; Yuko ISHIKAWA, Auteur ; Izumi HAMADA, Auteur ; Hideyuki SUGIOKA, Auteur ; Osamu YOTSUYA, Auteur ; Yushiro YAMASHITA, Auteur . - p.2784-2793.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2784-2793
Mots-clés : Autism spectrum disorder Melatonin Randomized controlled trial Sleep hygiene interventions Sleep problems Index. décimale : PER Périodiques Résumé : Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD). In a phase 3 randomized, placebo-controlled clinical trial, we administered 1-mg melatonin (n=65), 4-mg melatonin (n=65), or placebo (n=66) to196 children with ASD once daily before bedtime under adequate sleep hygiene interventions. The primary outcome was sleep onset latency (SOL) assessed with the electronic sleep diary. SOL shortened significantly in the 1- and 4-mg melatonin groups compared to the placebo group (- 22.0, - 28.0, and - 5.0 min, respectively; p?0.0001 each). This therapeutic regimen of melatonin is a reasonable clinical approach to cope with ASD-emergent difficulties in children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05139-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=474 Melatonin use and the risk of self-harm and unintentional injuries in youths with and without psychiatric disorders / Marica LEONE in Journal of Child Psychology and Psychiatry, 64-7 (July 2023)
[article]
Titre : Melatonin use and the risk of self-harm and unintentional injuries in youths with and without psychiatric disorders Type de document : Texte imprimé et/ou numérique Auteurs : Marica LEONE, Auteur ; Ralf KUJA-HALKOLA, Auteur ; Tyra LAGERBERG, Auteur ; Johan BJUREBERG, Auteur ; Agnieszka BUTWICKA, Auteur ; Zheng CHANG, Auteur ; Henrik LARSSON, Auteur ; Brian M. D'ONOFRIO, Auteur ; Amy LEVAL, Auteur ; Sarah E. BERGEN, Auteur Article en page(s) : p.1027-1036 Langues : Anglais (eng) Mots-clés : Melatonin sleep injury self-harm depression anxiety Index. décimale : PER Périodiques Résumé : Background Sleep disorders in youth have been associated with increased risks of injury, including suicidal behavior. This study investigated whether melatonin, which is the most common medication for sleep disturbances in youth in Sweden, is associated with a decreased risk of injury. Methods This population-based cohort study included 25,575 youths who initiated melatonin treatment between ages 6 and 18. Poisson regression was used to estimate rate of injuries in the year prior to and following melatonin treatment initiation. A within-individual design was used to estimate relative risks by comparing injury risk in the last unmedicated month with injury risks in the 12months after medication initiation. Analyses were stratified by sex, injury type, psychiatric comorbidities and age at melatonin-treatment initiation. Results While body injuries, falls and transport accident rates were comparable in the year before and after melatonin-treatment initiation, the risk of self-harm was highest in the months immediately prior to medication, and decreased thereafter. This was particularly prominent among adolescents with depression and/or anxiety, with females displaying greater absolute risks than males. Compared to the last unmedicated month, the 12months post medication initiation had decreased relative risks for self-harm, with an IRR [95% CI] in the month following melatonin-treatment initiation of 0.46 [0.270.76] among adolescent females with psychiatric disorders, after excluding antidepressant users. Conclusions Decreased risk of intentional self-harm was observed following melatonin-treatment initiation among females with depression and anxiety, suggesting that sleep interventions could be considered in an effort to reduce risk of self-harm in this population. En ligne : https://doi.org/10.1111/jcpp.13785 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508
in Journal of Child Psychology and Psychiatry > 64-7 (July 2023) . - p.1027-1036[article] Melatonin use and the risk of self-harm and unintentional injuries in youths with and without psychiatric disorders [Texte imprimé et/ou numérique] / Marica LEONE, Auteur ; Ralf KUJA-HALKOLA, Auteur ; Tyra LAGERBERG, Auteur ; Johan BJUREBERG, Auteur ; Agnieszka BUTWICKA, Auteur ; Zheng CHANG, Auteur ; Henrik LARSSON, Auteur ; Brian M. D'ONOFRIO, Auteur ; Amy LEVAL, Auteur ; Sarah E. BERGEN, Auteur . - p.1027-1036.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 64-7 (July 2023) . - p.1027-1036
Mots-clés : Melatonin sleep injury self-harm depression anxiety Index. décimale : PER Périodiques Résumé : Background Sleep disorders in youth have been associated with increased risks of injury, including suicidal behavior. This study investigated whether melatonin, which is the most common medication for sleep disturbances in youth in Sweden, is associated with a decreased risk of injury. Methods This population-based cohort study included 25,575 youths who initiated melatonin treatment between ages 6 and 18. Poisson regression was used to estimate rate of injuries in the year prior to and following melatonin treatment initiation. A within-individual design was used to estimate relative risks by comparing injury risk in the last unmedicated month with injury risks in the 12months after medication initiation. Analyses were stratified by sex, injury type, psychiatric comorbidities and age at melatonin-treatment initiation. Results While body injuries, falls and transport accident rates were comparable in the year before and after melatonin-treatment initiation, the risk of self-harm was highest in the months immediately prior to medication, and decreased thereafter. This was particularly prominent among adolescents with depression and/or anxiety, with females displaying greater absolute risks than males. Compared to the last unmedicated month, the 12months post medication initiation had decreased relative risks for self-harm, with an IRR [95% CI] in the month following melatonin-treatment initiation of 0.46 [0.270.76] among adolescent females with psychiatric disorders, after excluding antidepressant users. Conclusions Decreased risk of intentional self-harm was observed following melatonin-treatment initiation among females with depression and anxiety, suggesting that sleep interventions could be considered in an effort to reduce risk of self-harm in this population. En ligne : https://doi.org/10.1111/jcpp.13785 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=508 Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial / Barry WRIGHT in Journal of Autism and Developmental Disorders, 41-2 (February 2011)
[article]
Titre : Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial Type de document : Texte imprimé et/ou numérique Auteurs : Barry WRIGHT, Auteur ; David SIMS, Auteur ; Siobhan SMART, Auteur ; Ahmed ALWAZEER, Auteur ; Ben ALDERSON-DAY, Auteur ; Victoria ALLGAR, Auteur ; Clare WHITTON, Auteur ; Heather TOMLINSON, Auteur ; Sophie D. BENNETT, Auteur ; Jenni JARDINE, Auteur ; Nicola MCAFFREY, Auteur ; Charlotte LEYLAND, Auteur ; Christine JAKEMAN, Auteur ; Jeremy N.V. MILES, Auteur Année de publication : 2011 Article en page(s) : p.175-184 Langues : Anglais (eng) Mots-clés : Melatonin Sleep Autism spectrum disorders Dysomnia Index. décimale : PER Périodiques Résumé : Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms. En ligne : http://dx.doi.org/10.1007/s10803-010-1036-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=117
in Journal of Autism and Developmental Disorders > 41-2 (February 2011) . - p.175-184[article] Melatonin Versus Placebo in Children with Autism Spectrum Conditions and Severe Sleep Problems Not Amenable to Behaviour Management Strategies: A Randomised Controlled Crossover Trial [Texte imprimé et/ou numérique] / Barry WRIGHT, Auteur ; David SIMS, Auteur ; Siobhan SMART, Auteur ; Ahmed ALWAZEER, Auteur ; Ben ALDERSON-DAY, Auteur ; Victoria ALLGAR, Auteur ; Clare WHITTON, Auteur ; Heather TOMLINSON, Auteur ; Sophie D. BENNETT, Auteur ; Jenni JARDINE, Auteur ; Nicola MCAFFREY, Auteur ; Charlotte LEYLAND, Auteur ; Christine JAKEMAN, Auteur ; Jeremy N.V. MILES, Auteur . - 2011 . - p.175-184.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 41-2 (February 2011) . - p.175-184
Mots-clés : Melatonin Sleep Autism spectrum disorders Dysomnia Index. décimale : PER Périodiques Résumé : Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms. En ligne : http://dx.doi.org/10.1007/s10803-010-1036-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=117 Erratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes / Beth A. MALOW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)
PermalinkUrinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism / F. GEVI in Molecular Autism, 7 (2016)
PermalinkBrief Report: A Gene Enrichment Approach Applied to Sleep and Autism / Emily A. ABEL in Journal of Autism and Developmental Disorders, 50-5 (May 2020)
PermalinkCharacterizing Sleep in Adolescents and Adults with Autism Spectrum Disorders / S. E. GOLDMAN in Journal of Autism and Developmental Disorders, 47-6 (June 2017)
PermalinkThe treatment of sleep problems in autistic adults in the United Kingdom / E. HALSTEAD in Autism, 25-8 (November 2021)
Permalink